Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10088199rdf:typepubmed:Citationlld:pubmed
pubmed-article:10088199lifeskim:mentionsumls-concept:C1135183lld:lifeskim
pubmed-article:10088199lifeskim:mentionsumls-concept:C0079281lld:lifeskim
pubmed-article:10088199lifeskim:mentionsumls-concept:C0205042lld:lifeskim
pubmed-article:10088199lifeskim:mentionsumls-concept:C0018338lld:lifeskim
pubmed-article:10088199lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:10088199lifeskim:mentionsumls-concept:C0450442lld:lifeskim
pubmed-article:10088199lifeskim:mentionsumls-concept:C0439596lld:lifeskim
pubmed-article:10088199lifeskim:mentionsumls-concept:C1140999lld:lifeskim
pubmed-article:10088199pubmed:issue8lld:pubmed
pubmed-article:10088199pubmed:dateCreated1999-5-21lld:pubmed
pubmed-article:10088199pubmed:abstractTextIn the coronary circulation, endothelin-1 (ET-1) evokes spasms which are difficult to treat when the endothelial integrity is compromised. This study compares several classes of relaxing agents on already established contractions to ET-1 in an in vitro model using ring segments of the porcine left descending coronary artery (pLAD). All segments were precontracted with 10 nmol/L ET-1. The calcium channel blocker isradipine was 300 times more potent than verapamil, but was only a partial relaxant; the maximal relaxation obtained was 52 +/- 2% (n = 6). Atrial natriuretic peptide (ANP) was an equally potent relaxant of the ET-1 contraction; however, it too was an incomplete relaxant, maximal relaxation being < 60%. A 50% relaxation of the ET-1 contraction was obtained with 0.28 +/- 0.24 mumol/L ANP, n = 4 (IC50). Comparison of cyclic nucleotide analogues revealed a 30 times higher potency for 8-bromo-cyclic guanosine monophosphate (8-Br-cGMP)(IC50 44 +/- 11 mumol/L, n = 6) than for 8-bromo-cyclic adenosine monophosphate (8-Bi-cAMP) (IC50 1600 mumol/L, n = 6). The cyclic nucleotide phosphodiesterase (PDE) inhibitor milrinone, a PDE 3-inhibitor with an IC50 2.4 +/- 1.8 mumol/L, (n = 6) was 10 times more potent than rolipram (PDE 4-inhibitor), zaprinast (PDE 5-inhibitor) and vinpocentine (PDE 1-inhibitor). Withdrawal of these analogues and inhibitors from segments continuously exposed to 10 nmol/l ET-1 revealed that vinpocentine and 8-Br-cGMP were irreversible relaxants, in contrast to milrinone and 8-Br-cAMP. In conclusion, this study has demonstrated that cGMP-enhancing agents, such as the naturally occurring ANP, the calcium channel blocker isradipine, and the synthetic inhibitor of PDE 3, were the most effective relaxants of ET-1 evoked contractions in pLAD in vitro.lld:pubmed
pubmed-article:10088199pubmed:languageenglld:pubmed
pubmed-article:10088199pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:citationSubsetIMlld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10088199pubmed:statusMEDLINElld:pubmed
pubmed-article:10088199pubmed:monthDeclld:pubmed
pubmed-article:10088199pubmed:issn0036-5513lld:pubmed
pubmed-article:10088199pubmed:authorpubmed-author:HelleK BKBlld:pubmed
pubmed-article:10088199pubmed:authorpubmed-author:AardalSSlld:pubmed
pubmed-article:10088199pubmed:authorpubmed-author:Lillest?lI...lld:pubmed
pubmed-article:10088199pubmed:issnTypePrintlld:pubmed
pubmed-article:10088199pubmed:volume58lld:pubmed
pubmed-article:10088199pubmed:ownerNLMlld:pubmed
pubmed-article:10088199pubmed:authorsCompleteYlld:pubmed
pubmed-article:10088199pubmed:pagination625-34lld:pubmed
pubmed-article:10088199pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:meshHeadingpubmed-meshheading:10088199...lld:pubmed
pubmed-article:10088199pubmed:year1998lld:pubmed
pubmed-article:10088199pubmed:articleTitleRelaxing effects of cyclic GMP and cyclic AMP-enhancing agents on the long-lasting contraction to endothelin-1 in the porcine coronary artery.lld:pubmed
pubmed-article:10088199pubmed:affiliationDepartment of Surgery, University of Bergen, Norway.lld:pubmed
pubmed-article:10088199pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10088199pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:10088199pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed